Prodrugs of olpinapone

Specific phosphate derivatives of opicapone with improved solubility and stability address bioavailability challenges, offering enhanced treatment efficacy for neurological disorders through novel synthesis methods.

CN119095860APending Publication Date: 2024-12-06BIAL PORTELA & CA SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031158.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-01
Filing Date
2023-03-31
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing formulations of opicapone, a COMT inhibitor, face challenges in maximizing bioavailability, solubility, and stability, with prior synthesis methods yielding low purity and stability issues, making it difficult to effectively treat central and peripheral nervous system disorders.

Method used

Development of specific phosphate derivatives of opicapone and their pharmaceutically acceptable salts, which exhibit improved solubility and stability, synthesized through novel methods that stabilize the pyridine N-oxide portion, allowing for higher yields and conversion to opicapone in vivo.

Benefits of technology

The phosphate derivatives show at least 100 times improved solubility in water and stability in physiological conditions, providing enhanced bioavailability and pharmacokinetic profiles, effectively treating conditions like Parkinson's disease with reduced dosages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005063678570000041
    Figure BDA0005063678570000041
  • Figure BDA0005063678570000042
    Figure BDA0005063678570000042
  • Figure BDA0005063678570000051
    Figure BDA0005063678570000051
Patent Text Reader

Abstract

The present invention relates to prodrugs of olpinapone, synthetic intermediates thereof, and pharmaceutically acceptable salts thereof. The present invention also relates to processes for the preparation of the prodrugs of olpiapone and pharmaceutically acceptable salts thereof. In particular, the present invention relates to specific phosphate prodrugs of olpinapone, pharmaceutically acceptable salts thereof, and synthetic intermediates thereof, as well as processes for the preparation of said substances. The present invention also relates to a route of administration of a prodrug of olpinapone.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a prodrug of opicapone, a synthetic intermediate thereof and a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing a prodrug of opicapone and a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a specific phosphate prodrug of opicapone, a pharmaceutically acceptable salt thereof and a synthetic intermediate thereof, and a method for preparing the substance. The present invention also relates to a route of administration of a prodrug of opicapone. Background of the Invention

[0003] Levodopa (Levodopa, L-DOPA) has been used in clinical practice for the symptomatic treatment of various diseases including Parkinson's disease for decades. L-DOPA can cross the blood-brain barrier and then be converted into dopamine by amino acid decarboxylase (AADC), thereby increasing the dopamine level in the brain. However, the conversion of L-DOPA to dopamine may also occur in peripheral tissues, thereby possibly causing harmful effects. Therefore, it has become standard clinical practice to co-administer peripheral AADC inhibitors (such as carbidopa or benserazide), which prevent conversion to dopamine in peripheral tissues. It is also known that inhibitors of catechol-O-methyltransferase (COMT) can provide clinical improvement in patients with Parkinson's disease who are undergoing L-DOPA treatment, because COMT catalyzes the degradation of L-DOPA into inactive metabolites 3-O-methyldopa.

[0004] Opicapone is an effective and long-acting COMT inhibitor. It is bioactive, bioavailable and exhibits low toxicity. This is partly due to pyridine N-oxide, which is unusual in active pharmaceutical ingredients because of its high chemical and biological reactivity. Opicapone has potentially valuable drug properties in the treatment of some central and peripheral nervous system disorders, in which the inhibition of COMT may have therapeutic benefits, such as mood disorders; movement disorders, such as Parkinson's disease, Parkinson's disorder and restless legs syndrome; gastrointestinal disorders; edema formation state; and hypertension. The development of Opicapone is described in LEKiss et al., J.Med.Chem., 2010, 53, 3396-3411, and was approved in the European Union in June 2016 and in the United States in April 2020 for use in combination with L-DOPA for the treatment of Parkinson's disease.

[0005] WO 2007 / 013830 first disclosed opicapone and relates to its use in the treatment of central and peripheral nervous system disorders. WO 2008 / 094053 discloses that opicapone has good pharmacokinetic properties, allowing it to be administered once a day. WO 2013 / 089573 discloses that micronization can be used to provide good oral bioavailability. In view of the improved size, opicapone is manufactured and sold in micronized crystalline form. However, although opicapone can be used to treat central and peripheral nervous system disorders by oral administration of 25 or 50 mg daily doses, efforts are still being made to maximize its solubility, absorbance and distribution while minimizing its metabolism and excretion, thereby improving its pharmacokinetic profile.

[0006] Since WO 2007 / 013830 teaches that the reduced pyridine analogue is more toxic, it is important to prevent reduction of opicapone to this metabolite.

[0007] Water-soluble derivatives of other COMT inhibitors containing a nitrocatechol moiety have been contemplated. J. et al., Bioorg.Med.Chem.Lett.10 (2000), 1967-1969 describes the synthesis of water-soluble derivatives of entacapone. Specifically, it discloses the synthesis of entacapone monophosphate via the reaction of entacapone with phosphorus oxychloride in dry pyridine. However, the yield is very low (45%), many common synthesis strategies fail, and the phosphorylation site is not confirmed. In addition, the conversion of the prodrug only recovers about 60% of the entacapone, and the rest is converted into the active metabolite Z-entacapone. Perhaps for these reasons, no prodrug form of entacapone has been developed into a viable drug in the 20 years since the disclosure. WO 2019 / 195761 describes various prodrugs of tolcapone. However, most are uncharged to ensure retention in the eye and corneal permeability. WO 2019 / 195761 discloses phosphate derivatives of tolcapone when prepared in THF and pyridine using phosphorus oxychloride. The compounds have not been characterized, and the yield and purity are not disclosed. WO 2019 / 195761 is about the topical administration of prodrugs in the treatment of presbyopia and cataracts. Therefore, it is not related to the use of COMT inhibitors to treat central and peripheral nervous system disorders, which do not seem to be suitable for prodrug methods. Therefore, before the present invention, it was not clear whether the prodrug method would be applicable for COMT inhibitors used to treat central and peripheral nervous system disorders, or whether specific phosphate derivatives of opicapone could be reliably synthesized.

[0008] WO 2021 / 182981 identifies specific "clumped aggregates" that can negatively impact the bioavailability of individual formulations of micronized crystalline opicapone, and discloses methods for detecting and removing the clumped aggregates. WO 2022 / 025781 discloses kinetically soluble and bioavailable solid dispersions of opicapone.

[0009] Thus, maximizing the bioavailability of opicapone remains an active area of ​​research, and there remains a need for stable forms of opicapone that have improved bioavailability and that can be reliably synthesized in good yields. Summary of the invention

[0010] The present inventors have identified specific opicapone derivatives that have improved solubility compared to opicapone itself, such as certain specific phosphate derivatives of opicapone and pharmaceutically acceptable salts thereof.

[0011] Compared with opicapone itself, the phosphate derivatives of the present invention and pharmaceutically acceptable salts thereof show improved solubility in water. Preferably, the solubility (mg / ml) of the phosphate derivatives of opicapone and pharmaceutically acceptable salts thereof in pure water is increased by at least 100 times compared with opicapone itself. In addition, the phosphate derivatives of opicapone and pharmaceutically acceptable salts thereof are preferably stable in potassium buffer solution at pH=7.4, rat / human plasma, and rat / human liver S9 fraction (i.e., the supernatant fraction obtained from the liver by centrifugation at 9000g, the supernatant fraction containing cytoplasm and microsomes), but are easily converted to opicapone in rat liver homogenate. Therefore, the phosphate derivatives of opicapone and pharmaceutically acceptable salts thereof can act as prodrugs of opicapone in vivo.

[0012] The present inventors have also identified methods for synthesizing specific water-soluble prodrugs of opicapone and pharmaceutically acceptable salts thereof.

[0013] The inventors have found that the methods used in the prior art for synthesizing water-soluble prodrugs of COMT inhibitors are not suitable for synthesizing phosphate prodrugs of opicapone. This is due to the reaction of phosphorus oxychloride (POCl3) with the pyridine N-oxide portion of opicapone. It has been reported in the literature that POCl3 can be used to convert 2-picoline-N-oxide into the corresponding 2-(chloromethyl)pyridine derivatives (Redl, S. et al., J. Het. Chem., 43 (6), 1447-1453; 2006).

[0014] The present inventors have also determined that different opicapone prodrugs have different pharmacokinetic properties depending on the route of administration.

[0015] Thus, in a first general embodiment, the present invention provides a compound of formula (I):

[0016]

[0017] or a pharmaceutically acceptable salt thereof;

[0018] wherein R is H or C1-C6 alkyl and n is 0 or 1.

[0019] In a second general embodiment, the present invention provides a process for preparing a compound of formula (I) as described above or a pharmaceutically acceptable salt thereof, the process comprising deprotecting a compound of formula (II):

[0020]

[0021] wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1.

[0022] In a third general embodiment, the present invention provides a process for preparing a compound of formula (II) as described above, said process comprising reacting opicapone, a compound of formula (III):

[0023]

[0024] Reaction with a compound of formula (IV):

[0025]

[0026] wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1.

[0027] In a fourth general embodiment, the present invention provides a compound of formula (II) as described above, wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or C1-C6 alkyl and n is 0 or 1.

[0028] In a fifth general embodiment, the invention provides a pharmaceutical formulation for intravenous administration to a human, the pharmaceutical formulation comprising:

[0029] a. a compound of formula (I) as described above or a pharmaceutically acceptable salt thereof; and

[0030] b. Pharmaceutically acceptable vehicles.

[0031] In a sixth general embodiment, the invention provides a pharmaceutical formulation for subcutaneous administration to a human, the pharmaceutical formulation comprising:

[0032] a. a compound of formula (I) as described above or a pharmaceutically acceptable salt thereof; and

[0033] b. Pharmaceutically acceptable vehicles.

[0034] In a seventh general embodiment, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical formulation of a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating Parkinson's disease, preferably wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a daily dose equivalent to less than 50 mg of opicapone per day, preferably less than 25 mg of opicapone per day. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] The present invention will now be described in detail with reference to the accompanying drawings, in which:

[0036] Figure 1 The stability of compound 1 and compound 4 in different matrices is shown. Figure 1 a shows the clearance of compound 1 in different matrices (buffer ●; rat liver homogenate ■; human plasma ▼; rat plasma ◆; human liver S9 fraction ○) over a 1 hour period, measured at 0 h, 0.1 h, 0.25 h, 0.5 h, 0.75 h and 1 h. Compound concentration = 1 μM. Figure 1 b shows the clearance of Compound 1 (●) and Compound 4 (■) in rat liver homogenate over a 1 hour period, measured at 0 h, 0.1 h, 0.25 h, 0.5 h, 0.75 h and 1 h. Compound concentration = 1 μM.

[0037] Figure 2 The stability of Compound 1 and Compound 4 at different pH values ​​is shown (2500 ng / mL, at pH values ​​of 1.2 (●), 4.5 (■), and 6.8 (▲) for 4 hours at 37°C). Figure 2 a shows that compound 1 is stable in buffers of pH 1.2, pH 4.5, and 6.8, but takes some time to dissolve at pH 1.2. Figure 2 b shows that compound 4 is stable in buffers at pH 1.2 (●), 4.5 (■), and 6.8 (▲).

[0038] Figure 3 Shown are the oral pharmacokinetic properties of Compound 1 and Compound 4 in rats compared to micronized crystalline opicapone (3 mg / kg; 0.2% HPMC). Figure 3a shows that compound 1 (●) exhibits improved pharmacokinetic properties compared to compound 4 (■). Figure 3 b shows the conversion of Compound 1 (●) and Compound 4 (■) to opicapone, where Compound 1 produces an opicapone pharmacokinetic profile similar to opicapone itself. Compound 4 exhibits the worst oral pharmacokinetic parameters compared to Compound 1 and opicapone.

[0039] Figure 4 Shown are the intravenous pharmacokinetic properties of Compound 1 and Compound 4 in rats compared to micronized crystalline opicapone (1 mg / kg; DMSO:20% HPBCD (1:9)). Figure 4 a shows that compound 1 (●) exhibits improved pharmacokinetic properties compared to compound 4 (■). Figure 4 b shows the conversion of Compound 1 (○) and Compound 4 (□) to opicapone, where Compound 1 produces an opicapone pharmacokinetic profile similar to opicapone itself (▲). Compared with Compound 1 and opicapone, Compound 4 exhibited the worst intravenous pharmacokinetic parameters.

[0040] Figure 5 Shown are the subcutaneous pharmacokinetic properties of Compound 1 and Compound 4 in rats (3 mg / kg; DMSO:20% HPBCD (1:9)) compared to the oral pharmacokinetic properties of micronized crystalline opicapone. Figure 5 a shows the conversion of compound 1 (●) to opicapone (○), resulting in an opicapone pharmacokinetic profile with improved exposure (approximately 3-fold increase) when compared to opicapone itself (▲). Figure 5 b shows the conversion of compound 4 (■) to opicapone (□), resulting in an opicapone pharmacokinetic profile with improved exposure (approximately 3-fold increase) when compared to opicapone itself (▲).

[0041] Figure 6 The pharmacodynamic properties of compound 1 and compound 4 based on COMT inhibition are shown. Compound 1 (●) and compound 4 (■) are converted into opicapone to produce rapid inhibition of COMT activity in erythrocytes, with a maximum effect 2h after administration (96% and 94% inhibition for compound 1 and compound 4, respectively). At least until 8h after administration, the inhibition of COMT is maintained above 80%. The COMT inhibition of compound 1 and compound 4 is higher and more persistent than that of orally administered opicapone (●).

[0042] Figure 7 The pharmacodynamic properties of compound 4 based on L-DOPA bioavailability and 3-OMD compared to vehicle are shown. Figure 7a shows the pharmacodynamic properties of compound 4 (■) based on L-DOPA bioavailability compared to vehicle (□). Figure 7 b shows the pharmacodynamic properties of compound 4 (■) generated based on 3-OMD compared with vehicle (□). Concomitant administration of L-DOPA / benserazide increased circulating levels of L-DOPA (AUC 最后 increased by 1.7 times), and the levels of its metabolites decreased accordingly. DETAILED DESCRIPTION

[0043] A. Definition

[0044] Unless otherwise limited in specific instances, the following definitions apply to the terms as used throughout this specification.

[0045] The term "prodrug" refers to a pharmacologically inactive compound that is converted into a compound having the desired pharmacological activity by enzymatic and / or chemical reactions in vivo, which then exerts the desired pharmacological effect.

[0046] The term "protecting group" refers to a chemical moiety introduced onto a functional group to block its reactivity under synthetic conditions required to make changes elsewhere on the molecule. Protecting groups are stable to certain chemical conditions but can be readily removed under specific conditions in a process known as "deprotection".

[0047] The term "phosphate protecting group" refers to a protecting group as described above that has been introduced onto a phosphate functional group. Common examples of moieties used as phosphate protecting groups are C1-C6 alkyl and benzyl.

[0048] The term "C1-C6 alkyl" means a monovalent unsubstituted saturated straight or branched chain hydrocarbon group having 1 to 6 carbon atoms. "C1-C2 alkyl", "C1-C3 alkyl", "C1-C4 alkyl" and "C1-C5 alkyl" have similar meanings. Common examples used as phosphate protecting groups include methyl (C1) and tert-butyl (C4).

[0049] The term "pharmaceutically acceptable salts" means salts such as those described in standard texts on salt formation, see for example: P. Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection and Use (VCHA / Wiley-VCH, 2002) or SM Berge et al., "Pharmaceutical Salts" (1977) Journal of Pharmaceutical Sciences, 66, 1-19.

[0050] The term "pharmaceutically acceptable excipient" means any ingredient in a pharmaceutical composition other than one or more compounds of the invention or other known pharmacologically active ingredients. The choice of excipient will largely depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

[0051] The term "vehicle" means a carrier or inert medium used as a solvent in which a medically active agent is formulated and or administered in liquid form (Dictionary of Pharmacy, 1986). The term "pharmaceutically acceptable vehicle" means any vehicle that can be used to prepare a liquid pharmaceutical formulation, which is generally compatible with the other ingredients of the formulation and does not produce adverse reactions when administered to a human. It comprises a solvent (e.g., water) and optionally one or more pharmaceutically acceptable excipients (e.g., one or more buffers, one or more surfactants, one or more preservatives, etc.).

[0052] The terms "therapy," "treatment," and "treatment" include both preventative and curative treatment of a disorder, disease, or condition. It also includes slowing, interrupting, controlling, or stopping the progression of a disorder, disease, or condition. It also includes preventing, curing, slowing, interrupting, controlling, or stopping the symptoms of a disorder, disease, or condition.

[0053] Where it is desired to administer one therapeutic agent "in combination with another therapeutic agent," this means that they must be administered in such a manner that both therapeutic agents are present in the patient's body at the same time. The two agents may be administered as a single formulation or as separate formulations and simultaneously or subsequently via the same or different routes of administration.

[0054] The "effective daily dose" of a compound is the total amount of the compound that must be administered daily over the entire course of treatment to provide the desired pharmacological (and therefore therapeutic) effect. The effective daily dose can be administered as one or more discrete doses that add together to achieve the effective daily dose, or it can be administered in the form of a continuous infusion.

[0055] B. Water-soluble prodrugs of opicapone and their precursors

[0056] The present invention relates to a compound of formula (I):

[0057]

[0058] or a pharmaceutically acceptable salt thereof; wherein R is H or C1-C6 alkyl and n is 0 or 1. The present inventors have discovered that the compound of formula (I) acts as a prodrug of opicapone by remaining stable in buffer solution yet converting back to opicapone in rat liver homogenate.

[0059] In one embodiment, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein n is 0.

[0060] In another embodiment, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein n is 1. In a preferred embodiment, wherein n is 1, R is H. In an alternative embodiment, wherein n is 1, R is C1-C6 alkyl, preferably C1-C4 alkyl, more preferably C1-C2 alkyl, even more preferably methyl.

[0061] The pharmaceutically acceptable salt of the compound of formula (I) is preferably selected from the group consisting of sodium salt, ammonium salt or potassium salt. In a more preferred embodiment, its pharmaceutically acceptable salt is selected from the group consisting of sodium salt and ammonium salt. For example, its pharmaceutically acceptable salt is sodium salt. For example, its pharmaceutically acceptable salt is ammonium salt. In a more preferred embodiment, the sodium salt is disodium salt and the ammonium salt is triammonium salt. These salts of opicapone prodrugs are found to be stable, soluble and non-toxic.

[0062] The compound of formula (I) can be prepared from the compound of formula (II):

[0063]

[0064] wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1. The inventors surprisingly found that the prior art methods for phosphorylating entacapone and tolcapone are not suitable for directly phosphorylating opicapone to provide the compound of formula (I). However, by first forming an intermediate compound of formula (II), the compound of formula (I) can be isolated in high yield and high purity without changing the main pyridine N-oxide part.

[0065] In a preferred embodiment, the phosphate protecting groups are each independently selected from the group consisting of C1-C6 alkyl and benzyl. In a more preferred embodiment, the phosphate protecting groups are identical and selected from the group consisting of methyl, tert-butyl and benzyl. In an alternative more preferred embodiment, the phosphate protecting groups are identical and are ethyl. In an even more preferred embodiment, the phosphate protecting groups are all benzyl or all tert-butyl.

[0066] C. Methods for synthesizing water-soluble prodrugs of opicapone and pharmaceutically acceptable salts thereof

[0067] The present invention also relates to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, the process comprising (a) deprotecting a compound of formula (II) as defined above to provide a compound of formula (I), and (b) optionally converting the compound of formula (I) into a pharmaceutically acceptable salt.

[0068] The deprotection step can be performed using any of the following methods: deprotection using a boron agent such as boron tribromide; deprotection using a trimethylsilyl halide; deprotection via hydrolysis using a strong acid such as hydrogen bromide (HBr) or hydrochloric acid (HCl); deprotection via oxidation using an oxidant such as cerium ammonium nitrate (CAN); or deprotection via catalytic hydrogenolysis, wherein the catalyst is selected from the group consisting of palladium on carbon or platinum (IV) oxide. For example, deprotection using a boron agent. For example, deprotection using a trimethylsilyl halide. For example, deprotection via hydrolysis using a strong acid such as hydrogen bromide (HBr) or hydrochloric acid (HCl). For example, deprotection via catalytic hydrogenolysis, wherein the catalyst is selected from the group consisting of palladium on carbon or platinum (IV) oxide. In a preferred embodiment, the deprotection step is performed using a trimethylsilyl halide. In a more preferred embodiment, the trimethylsilyl halide is trimethylsilyl bromide.

[0069] In a preferred embodiment, the method for preparing the compound of formula (I) comprises deprotecting the compound of formula (II) using a trimethylsilyl halide in an aprotic solvent, followed by aqueous post-treatment. In a more preferred embodiment, the trimethylsilyl halide is trimethylsilyl bromide. In a preferred embodiment, the aprotic solvent may be selected from the group consisting of dichloromethane and acetonitrile. In a more preferred embodiment, the aprotic solvent is dichloromethane. In a most preferred embodiment, the trimethylsilyl halide is trimethylsilyl bromide and the aprotic solvent is dichloromethane.

[0070] The optimal reaction temperature depends on the structures of R1, R2, R and n in the compound of formula (II). Preferably, the reaction temperature is in the range of 10°C to 25°C. In a more preferred embodiment, the reaction temperature is at a controlled temperature of 20 to 25°C, more preferably at room temperature (rt) of 25°C.

[0071] Preferably, the compound of formula (I) is purified by reverse phase chromatography, for example using a C18 reverse phase column and a water / acetonitrile gradient of the mobile phase. Alternatively, the compound of formula (I) (e.g., compound 1) is converted into an equivalent amine salt (e.g., compound 3) by adding aqueous ammonia (e.g., 30% aqueous ammonia) to precipitate the product. Pure amine salts (e.g., compound 3) can be converted into compounds of formula (I) (e.g., compound 1) by adding strong acids (e.g., HCl).

[0072] The present invention also extends to a process for preparing a pharmaceutically acceptable salt of a compound of formula (I).

[0073] In one embodiment, the present invention relates to a method for preparing the sodium salt of a compound of formula (I), the method comprising reacting a compound of formula (I) with sodium hydroxide in a suitable solvent system. For example, the suitable solvent system is ethanol.

[0074] In one embodiment, the present invention relates to a method for preparing an ammonium salt of a compound of formula (I), comprising reacting the compound of formula (I) with aqueous ammonia in a suitable solvent system. For example, a suitable solvent system is methanol and diethyl ether. Alternatively, a suitable solvent system is isopropanol and water and the ammonium salt of the compound of formula (I) is collected in the form of a precipitate.

[0075] D. Methods for synthesizing water-soluble prodrugs of opicapone and useful intermediates in the synthesis of pharmaceutically acceptable salts thereof

[0076] The present invention relates to a method for preparing a compound of formula (II), which comprises reacting a compound of formula (III) in the presence of a base and an aprotic solvent:

[0077]

[0078] Reaction with a compound of formula (IV):

[0079]

[0080] wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1.

[0081] In a preferred embodiment, the phosphate protecting groups are each independently selected from the group consisting of C1-C6 alkyl and benzyl. In a more preferred embodiment, the phosphate protecting groups are identical and selected from the group consisting of methyl, tert-butyl and benzyl. In an alternative more preferred embodiment, the phosphate protecting groups are identical and are ethyl. In an even more preferred embodiment, the phosphate protecting groups are all benzyl or all tert-butyl.

[0082] Preferably, the compound of formula (II) is purified by column chromatography, for example using a silica stationary phase and a methanol / dichloromethane mixture as mobile phase.

[0083] In another embodiment, the base may be selected from the group consisting of trimethylamine or Hunig's base (N,N-diisopropylethylamine). In a preferred embodiment, the base is trimethylamine (TEA).

[0084] In another embodiment, the aprotic solvent may be selected from the group consisting of dichloromethane, tetrahydrofuran, acetonitrile and ethyl acetate. In a preferred embodiment, the aprotic solvent is dichloromethane.

[0085] Preferably, the reaction temperature is in the range of 10° C. to 25° C. In a more preferred embodiment, the reaction temperature is at a controlled temperature of 20 to 25° C., more preferably at room temperature (rt) of 25° C.

[0086] As will be clear to the skilled person, the method for preparing a compound of formula (II) comprising reacting a compound of formula (III) with a compound of formula (IV) can be directly combined with a method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, the method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof comprising deprotecting the compound of formula (II) and optionally converting the product into a pharmaceutically acceptable salt. In the combined method, the compound of formula (II) may be purified by column chromatography prior to deprotection.

[0087] In the method described above, R1 and R2 are preferably each independently selected from the group consisting of C1-C6 alkyl and benzyl. In a more preferred embodiment, the phosphate protecting groups are identical and selected from the group consisting of methyl, tert-butyl and benzyl. In an alternative more preferred embodiment, the phosphate protecting groups are identical and are ethyl. In an even more preferred embodiment, the phosphate protecting groups are all benzyl or all tert-butyl.

[0088] In one embodiment, the invention relates to a process for preparing a compound of formula (II), comprising reacting a compound of formula (III) with a compound of formula (IV); wherein n is 0.

[0089] In another embodiment, the present invention relates to a method for preparing a compound of formula (II), the method comprising reacting a compound of formula (III) with a compound of formula (IV); wherein n is 1. In a preferred embodiment, wherein n is 1, R is H. In an alternative embodiment, wherein n is 1, R is C1-C6 alkyl, preferably C1-C4 alkyl, more preferably C1-C2 alkyl, even more preferably methyl.

[0090] E. Pharmaceutical preparations of water-soluble prodrugs of opicapone and pharmaceutically acceptable salts thereof

[0091] The present invention relates to a pharmaceutical preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The pharmaceutical preparation can be in solid form, such as tablets or capsules, or in liquid form or in semi-solid form, such as gel.

[0092] In a preferred embodiment, the present invention relates to a pharmaceutical formulation for intravenous, subcutaneous, intraperitoneal or intraduodenal administration (preferably to humans), more preferably intravenous or subcutaneous administration, most preferably subcutaneous administration, comprising:

[0093] a. a compound of formula (I) as described above or a pharmaceutically acceptable salt thereof; and

[0094] b. Pharmaceutically acceptable vehicles.

[0095] In a preferred embodiment, the pharmaceutically acceptable vehicle is an aqueous solution. For example, the pharmaceutically acceptable vehicle may comprise water, optionally with one or more water-miscible solvents, such as ethanol, propylene glycol, polyethylene glycol, transcutol, glycerol or DMSO. The aqueous solution may also comprise one or more additives selected from the group consisting of NaCl (saline) and a buffer (e.g., phosphate buffer or sodium bicarbonate) to form an isotonic solution suitable for intravenous or subcutaneous administration (e.g., administration to humans), preferably suitable for subcutaneous administration (e.g., administration to humans) with a neutral pH value (pH 5 to 7).

[0096] In a specific embodiment, the present invention relates to a pharmaceutical formulation for intravenous or subcutaneous (preferably subcutaneous) administration, the pharmaceutical formulation comprising a compound of formula (I); preferably compound 1 or compound 4 (more preferably compound 4) and a pharmaceutically acceptable vehicle. The formulation may also comprise L-DOPA and / or carbidopa (preferably L-DOPA and carbidopa). Alternatively, the formulation may also comprise foslevodopa and / or foscarbidopa (preferably foslevodopa and foscarbidopa).

[0097] F. Therapeutic Uses

[0098] The present invention also relates to the compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical preparations of the compounds of formula (I) and pharmaceutically acceptable salts thereof as described above for use in treating Parkinson's disease.

[0099] In a preferred embodiment, the compound or pharmaceutical preparation is combined with L-DOPA or phospho-levodopa, more preferably L-DOPA or phospho-levodopa and a peripheral AADC inhibitor (such as carbidopa, phospho-carbidopa or benserazide). L-DOPA or phospho-levodopa and / or an AADC inhibitor may be administered alone or in combination with each other. In the case of administering the compound of formula (I) or a pharmaceutically acceptable salt thereof in the form of a solid (e.g., tablet or capsule), it may be administered together with L-DOPA or phospho-levodopa and / or an AADC inhibitor, but it is preferably administered separately from L-DOPA or phospho-levodopa and / or an AADC inhibitor. In the case of administering the compound of formula (I) in the form of an intravenous, subcutaneous or intraperitoneal liquid (preferably an intravenous or subcutaneous liquid, more preferably a subcutaneous liquid), it may be administered separately or concomitantly with L-DOPA or phospho-levodopa and / or an AADC inhibitor (in the form of a single daily administration or multiple daily administrations or continuous administration). In case the compound of formula (I) is administered in the form of an intraduodenal liquid, suspension or semisolid (e.g. a gel, preferably an intraduodenal gel or suspension, more preferably an intraduodenal gel), it may be administered separately or concomitantly with L-DOPA or phospho-L-DOPA and / or an AADC inhibitor.

[0100] In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered at an effective daily dose equivalent to less than 50 mg of opicapone per day. However, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered at an effective daily dose equivalent to 50 mg of opicapone per day. In a preferred embodiment, the compound of formula (I) has an effective daily dose equivalent to 1 to 30 mg of opicapone per day, more preferably equivalent to 2 to 25 mg per day, and even more preferably equivalent to 5 to 20 mg per day. In this context, the term "equivalent" means that the daily dose contains less than 50 mg of opicapone when the phosphate moiety and any associated counterions of its pharmaceutically acceptable salts are excluded on a mass basis.

[0101] The effective daily dose may be administered in the form of discrete doses (solid, liquid or semisolid, preferably liquid) or as a continuous liquid or semisolid infusion.

[0102] Subcutaneous injection has the advantage of being suitable for continuous administration, but is less invasive than intravenous or intraduodenal administration. This can improve the patient's health and / or compliance with treatment. However, the bioavailability of a particular compound or prodrug via a particular route cannot be predicted.

[0103] according to Figures 3 to 7Based on the data shown in , intravenous administration is preferred for compounds of formula (I). Specifically, for compounds of formula (I) wherein n is 0 (e.g., compound 1 or a salt thereof (such as compound 2 or compound 3)), intravenous administration is most preferred. In the case of administering a compound of formula (I) in the form of an intravenous liquid, it may be administered separately or concomitantly with L-DOPA or phospho-L-DOPA and / or an AADC inhibitor.

[0104] according to Figures 3 to 7 According to the data shown in , subcutaneous administration is preferred for compounds of formula (I). Specifically, subcutaneous administration is most preferred for compounds of formula (I) where n is 1 (e.g., compound 4). In the case of administering a compound of formula (I) in the form of a subcutaneous liquid, it may be administered separately or concomitantly with L-DOPA or phospho-levodopa and / or an AADC inhibitor. In a particularly preferred embodiment, the present invention provides compound 4 for the treatment of Parkinson's disease, wherein compound 4 is administered subcutaneously in combination with L-DOPA or phospho-levodopa, more preferably in combination with L-DOPA or phospho-levodopa and a peripheral AADC inhibitor (such as carbidopa, phospho-carbidopa or benserazide).

[0105] L-DOPA and / or AADC inhibitors are preferably administered in the form of intravenous, subcutaneous or intraperitoneal liquid (preferably subcutaneous or intravenous liquid, more preferably subcutaneous liquid). They themselves can be administered in the form of prodrugs. For example, L-DOPA can be administered in the form of phospho-levodopa (levodopa-4'-monophosphate). For example, AADC inhibitors can be administered in the form of phospho-carbidopa (carbidopa 4'-monophosphate). For example, L-DOPA can be administered in the form of phospho-levodopa and AADC inhibitors can be administered in the form of phospho-carbidopa. Phospho-levodopa and phospho-carbidopa can be administered in the form of binary compositions (e.g., phospho-levodopa / phospho-carbidopa; ABBV-951) together with separately administered compounds of formula (I). Phospho-levodopa, phospho-carbidopa and compounds of formula (I) can be administered in the form of ternary compositions (e.g., phospho-levodopa / phospho-carbidopa / compounds of formula (I)).

[0106] G. Examples

[0107] Preparation of intermediates

[0108] Compounds of formula (IV) -Diphenylmethyl chlorophosphate

[0109]

[0110] To a stirred solution of diphenylmethyl phosphate (1 mL, 1,187 g, 4.53 mmol) in toluene (20 mL) was added N-chlorosuccinimide. The reaction was stirred at room temperature for 3 h. Thereafter, succinimide was filtered out (through a short pad of celite) and the filtrate was evaporated to give diphenylmethyl chlorophosphate (1.6 g) as a colorless oil, which was used in the next step without further purification.

[0111] Compound of formula (III) -2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide

[0112] The synthesis of opicapone, ie the compound of formula (III), is described in WO 2007 / 013830 or WO 2013 / 089573. The method described in WO 2013 / 089573 is preferred.

[0113] Compound of formula (II) -3-(5-(3-((bis(ethoxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide

[0114]

[0115] A mixture of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (10 g, 24.2 mmol), diethyl chlorophosphate (4.59 g, 26.6 mmol) and triethylamine (10.12 mL, 72.6 mmol) in dichloromethane (100 mL) was mixed at 0° C., warmed to room temperature and stirred at this temperature overnight. The obtained brown solution was quenched with water (100 mL). The organic layer was washed with HCl 4M solution (2 x 100 mL), brine, dried over sodium sulfate, filtered and then evaporated to provide 11.6 g of the product 3-(5-(3-((bis(ethoxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide as a yellow solid.

[0116] Compound of formula (II) -3-(5-(3-((bis(benzyloxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide

[0117]

[0118] A mixture of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (1.559 g, 3.77 mmol), diphenylmethyl chlorophosphate (1.343 g, 4.53 mmol) and triethylamine (1.577 mL, 11.32 mmol) in dichloromethane (25 mL) was stirred at room temperature overnight. A few drops of methanol and water were added to the obtained brown solution. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then evaporated to give the crude product as an orange solid. Chromatographic purification on silica (in methanol / dichloromethane mixtures) provided 1.027 g of 3-(5-(3-((bis(benzyloxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide as an orange solid.

[0119] Compound of formula (II) -2,5-dichloro-3-(5-(3-(((di-tert-butoxyphosphoryl)oxy)methoxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide

[0120]

[0121] Sodium hydride (17.01 mg, 0.425 mmol) was added to a solution of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (160 mg, 0.387 mmol) in DMF (1 mL). After 10 min, DMF (1 mL) containing tetrabutylammonium iodide (100 mg, 0.271 mmol) and di-tert-butyl (chloromethyl) phosphate (120 mg, 0.464 mmol) was added and the mixture was stirred at room temperature for 1 h and at 50 °C for 1 h. After cooling, water containing 5% citric acid was slowly added and the solution was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered and evaporated to dryness. The resulting crude material was purified by flash column to obtain a soft yellow solid (95 mg, 27%) as the title compound.

[0122] Preparation of Opicapone prodrugs and pharmaceutically acceptable salts thereof

[0123] Compound of formula (I) -2,5-Dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (Compound 1)

[0124]

[0125] Trimethylsilyl bromide (183 mg, 0.155 mL, 1.195 mmol) was added to an ice-cold solution of 3-(5-(3-((bis(benzyloxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide (350 mg, 0.520 mmol) under a nitrogen atmosphere. After stirring at low temperature for 30 min, the reaction was quenched with a few drops of water and then evaporated. Reverse phase chromatography purification in acetonitrile-water (gradient elution, 0 to 10% acetonitrile) provided 105 mg of 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonyloxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (90% purity, yield: 37%) as a light yellow solid.

[0126] 1 H NMR (DMSO d6 ): 8.39(1H,d,J=2.2Hz), 8.18(1H,dd,J=1.2,2.2Hz), 2.66(3H,s), 2.24(3H,s).

[0127] 13 C NMR (DMSO d6 ): 174.8, 164.6, 150.4, 149.5 (d, J = 5.5Hz), 143.3 (d, J = 5.5Hz), 139.4, 139.3, 134.2, 131.1, 123.3 (d, J = 3Hz), 122.6, 120.3, 112.1, 17.9, 16.5.

[0128] Disodium salt of the compound of formula (I) -5-(3-(2,5-dichloro-4,6-dimethyl-1-pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2-hydroxy-3-nitrophenyl phosphate disodium salt (Compound 2)

[0129]

[0130] To a solution of 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (48 mg, 0.097 mmol) in absolute ethanol (3 mL) was added diethyl ether (3 mL), followed by the dropwise addition of 1 M sodium hydroxide (0.195 mL, 0.195 mmol) at 20-25° C. with stirring. After stirring for 15 min, the obtained solid was collected by filtration, washed with a mixture of ethanol-diethyl ether (1:1), and then dried in vacuo at 40° C. to give sodium 5-(3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2-hydroxy-3-nitrophenyl phosphate (47 mg, yield: 90%) as an orange powder.

[0131] 1 H NMR(D2O):8.37(1H,d,J=2.4Hz),7.83(1H,dd,J=1.4,2.4Hz),2.60(3H,s),2.15(3H,s)

[0132] 13 C NMR (D2O): 178.4, 165.4, 161.7 (d, J = 4Hz), 153.7, 149.0 (d, J = 6Hz), 142. 9,142.3,139.5,134.2,124.6,124.4,123.5(d,J=3Hz),108.0,19.5,17.9

[0133] Triammonium salt of the compound of formula (I) -2,5-Dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide triammonium salt (Compound 3)

[0134]

[0135] To a stirred solution of 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (20 mg, 0.041 mmol) in absolute ethanol (1 mL) was added a 2M solution of ammonia in methanol (0.101 mL, 0.203 mmol). After stirring for 15 min, the obtained solid was collected by filtration, washed with ethanol, and then dried in vacuo at 40 °C to give 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide triammonium salt (15 mg, yield: 68%) as an orange powder.

[0136] 1 H NMR (DMSO d6 ): 8.25 (1H, d, J = 2.4Hz), 7.67 (1H, dd, J = 0.7, 2.4Hz), 6.90 (12H, br), 2.66 (3H, s), 2.23 (3H, s).

[0137] 13 C NMR (DMSO d6 ): 176.7, 164.3 (d, J = 5Hz), 164.2, 150, 149.9 (d, J = 7Hz), 139.4, 137.1, 134.0, 130.9, 123.5, 121.9, 117.8 (d, J = 2.5Hz), 100.2, 17.9, 16.5.

[0138] Triammonium salt of the compound of formula (I) 2,5-Dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (Compound 3)

[0139]

[0140] To a solution of 3-(5-(3-((bis(ethoxy)phosphoryl)oxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide (5.00 g, 9.10 mmol) in DCM (100 mL) was added trimethylsilyl bromide (13.94 g, 12.01 mL, 91 mmol) at -10 °C and under nitrogen atmosphere. The mixture was warmed to 40 °C and allowed to stir at room temperature overnight. The solvent was evaporated and the solid was dissolved in a mixture of MeOH (50 mL) and water (5 mL) and evaporated again. The residue was dissolved in IPA 100 mL, and water (10 mL) and ammonia solution (30% aqueous solution, 5 mL) were added to the filtered clear solution to precipitate the product. The resulting suspension was heated to 70 °C and cooled to 0-5 °C and warmed to room temperature. The solid product was filtered and washed with IPA (2 x 20 mL), dried in vacuo at 2 mbar at 40 °C to provide 4.2 g of 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-(phosphonooxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide triammonium salt as an orange solid (90% purity, yield: 85%).

[0141] Compound of formula (I) -Compound 4: 2,5-dichloro-3-(5-(4-hydroxy-3-nitro-5-((phosphonooxy)methoxy)phenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide

[0142]

[0143] Trifluoroacetic acid (0.108 ml, 1.416 mmol) was added to a solution of 2,5-dichloro-3-(5-(3-(((di-tert-butoxyphosphoryl)oxy)methoxy)-4-hydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (90 mg, 0.142 mmol) in dichloromethane (1.5 ml) at 0 °C. The reaction mixture was stirred at room temperature for 45 min. The solvent was evaporated and the residue was purified by flash chromatography using a reverse phase column to obtain a light yellow solid (28 mg, 34%) as the desired compound.

[0144] 1 H NMR (DMSO d6 ): 8.37(1H,d,J=2.1Hz), 8.15(1H,d,J=2.1Hz), 5.68(2H,d,J=14.0Hz), 2.66(3H,s), 2.25(3H,s).

[0145] 13 C NMR (DMSO d6 ): 175.0, 164.6, 150.4, 149.3, 147.8, 139.4, 138.7, 134.1, 131.1, 122.7, 120.2, 119.9, 111.9, 90.2 (d, J = 4.5Hz), 17.9, 16.5.

[0146] The free form of a compound of formula (I) (eg Compound 1 or Compound 4) can be easily obtained from the relevant salt via acidification of the relevant salt.

[0147] Study on the solubility and stability of the prodrug of opicapone

[0148] Solubility studies

[0149] Aqueous solubility studies were completed for Compound 1, Compound 2 and Compound 3 as described above, as well as Opicapone itself. Solubility studies were completed at room temperature. To determine the solubility, increasing amounts of distilled water were added to 5 mg of the test sample until it was observed by the naked eye that it completely dissolved the product. A total of 0.8 mL of distilled water was sufficient to completely dissolve it, which corresponds to an approximate solubility of 6 mg / mL.

[0150] The results are shown in Table 1 below.

[0151] Table 1 - Solubility of opicapone and opicapone prodrugs at room temperature

[0152] Compound Solubility in pure water (mg / mL) Opicapon 0.023-0.036 Compound 1 6 Compound 2 >0.5 Compound 3 >0.5 Compound 4 >0.5

[0153] The solubility data in Table 1 demonstrate that Compounds 1 to 4 provide a significant increase in solubility in pure water compared to opicapone itself. Compound 1 exhibits a 160-fold increase in solubility in pure water compared to opicapone itself.

[0154] In vitro stability studies

[0155] The stability of 1 μM Compound 1 was evaluated in phosphate buffer, human plasma, rat plasma, human liver S9 fraction, rat liver S9 fraction, and rat liver homogenate.

[0156] Reactions were initiated by adding 1 μM of the test compound to the desired matrix (plasma, liver homogenate 0.4 g / mL or S9 fraction 1 mg / mL, respectively) in a final volume of 350 μL. At the following time points: 0, 5, 15, 30, 45, 60 min, 50 μL of sample was taken and 200 μL of the internal standard (opicapone) containing 1 μM was used. 13C6) was precipitated with acetonitrile (1% formic acid). The samples were centrifuged at 20,000 g for 10 min at 4°C and then analyzed by LC-MS / MS using a bioanalytical method previously developed in-house.

[0157] Using 50 mM potassium phosphate buffer (KPB), pH 7.4, a 10 μM solution of test compound was prepared by adding 1 μL of 10 mM compound stock to 999 μL KPB 50 mM.

[0158] Prepare a solution of 100 mM K2HPO4 by weighing 17.42 g and adding to 1 L of MilliQ water. Prepare a solution of 100 mM KH2PO4 by weighing 13.61 g and adding to 1 L of MilliQ water. To achieve pH 7.4, add about 250 ml of 100 mM KH2PO4 solution to 100 mM K2HPO4, and measure the pH value continuously. To prepare a solution of 50 mM potassium phosphate buffer, add 500 mL of 100 mM potassium phosphate buffer (pH 7.4) to 500 mL MilliQ water.

[0159] like Figure 1 As shown in a, after 0.75 h, compound 1 was stable in buffer, human plasma and rat plasma, and human liver S9 fraction and rat liver S9 fraction. However, in rat liver homogenate, compound 1 was successfully converted to opicapone. After 0.5 h, the percentage of the remaining parent compound was less than 25%.

[0160] The stability of 1 μM Compound 4 was evaluated in phosphate buffer, human plasma, rat plasma, human liver S9 fraction, rat liver S9 fraction, and rat liver homogenate.

[0161] Reactions were initiated by adding 1 μM of the test compound to the desired matrix (plasma or S9 fraction, 1 mg / mL) in a final volume of 250 μL. For plasma, 50 μL samples were taken at 0, 15, 30, 45, and 60 min of incubation and incubated with 100 μL of a 1 μM internal standard (opicapone) containing 1 μM of 13C6) acetonitrile (1% formic acid) composed of internal standard working solution (ISWS) for precipitation. For S9 part, take 50 μL of sample and precipitate with 100 μL of ISWS after incubation for 60 min. For rat liver homogenate (0.2 g / mL of protein), the reaction is initiated by adding a final volume of 350 μL of 1 μM test compound. At the following time points: incubate 0, 5, 15, 30, 45, 60 min, take 50 μL of sample and precipitate with 200 μL ISWS. The sample is centrifuged at 20,000g for 10 min at 4 ° C, and then analyzed by LC-MS / MS using the previously developed bioanalytical method. Compound 4 is stable in all matrices, with the exception of rat liver homogenate, where after 60 min of incubation, the remaining compound accounts for about 31%. Using 50 mM potassium phosphate buffer (KPB), pH 7.4, a 10 μM solution of test compound was prepared by adding 1 μL of 10 mM compound stock solution to 999 μL KPB 50 mM.

[0162] Prepare a solution of 100 mM K2HPO4 by weighing 17.42 g and adding to 1 L of MilliQ water. Prepare a solution of 100 mM KH2PO4 by weighing 13.61 g and adding to 1 L of MilliQ water. To achieve pH 7.4, add about 250 ml of 100 mM KH2PO4 solution to 100 mM K2HPO4, and measure the pH value continuously. To prepare a solution of 50 mM potassium phosphate buffer, add 500 mL of 100 mM potassium phosphate buffer (pH 7.4) to 500 mL MilliQ water.

[0163] After 0.75 h, compound 4 was stable in buffer, human plasma and rat plasma, and human liver S9 fraction and rat liver S9 fraction. Figure 1 As shown in b, compound 4 was successfully converted to opicapone in rat liver homogenate (along with a replicate experiment with compound 1).

[0164] The stability of Compound 1 and Compound 4 at 2500 ng / mL was evaluated at different pH values ​​of 1.2, 4.5, and 6.8 at 37°C for 4 hours.

[0165] The buffer solution was prepared as follows:

[0166] pH 1.2 Buffer Solution:

[0167] To prepare 1 L:

[0168] 3.73g potassium chloride

[0169] 7mL HCl 37%

[0170] Add purified water

[0171] Check pH / adjust pH to 1.20 ± 0.05 (solutions used: HCl 1M and / or NaOH 1M)

[0172] pH 4.5 buffer solution

[0173] To prepare 1 L:

[0174] 2.99g sodium acetate trihydrate

[0175] 14 mL acetic acid 2M

[0176] Add purified water

[0177] Check pH / adjust pH to 4.50 ± 0.05 (using solution: acetic acid 2M and / or NaOH 1M)

[0178] pH 6.8 buffer solution

[0179] To prepare 1 L:

[0180] 6.81g potassium dihydrogen phosphate

[0181] 22mL NaOH 1M

[0182] Add purified water

[0183] Check pH / adjust pH to 6.80 ± 0.05 (using solution: HCl 1M and / or NaOH 1M)

[0184] like Figure 2 As shown in Fig. 1, compound 1 is stable in buffers at pH 1.2, pH 4.5, and 6.8, but is not immediately soluble at pH 1.2. Figure 2 As shown in b, compound 4 is stable in buffers at pH 1.2, 4.5, and 6.8.

[0185] Solid-state long-term stability studies showed that compound 4 was particularly stable.

[0186] Pharmacokinetic properties of opicapone prodrugs

[0187] Oral pharmacokinetics

[0188] The pharmacokinetic properties of Compound 1 and Compound 4 compared to micronized crystalline opicapone were evaluated by oral administration (3 mg / kg; 0.2% HPMC) to 4 male Wistar rats.

[0189] During the study, blood was collected from the tail vein at different time points, centrifuged at 1500 x g for 15 min in a refrigerated centrifuge (4°C), and the obtained plasma was stored at -80°C until further analysis. The collected plasma samples were analyzed for compound 1, compound 4, and opicapone exposure. Bioanalysis involved the use of LC-MS / MS after plasma precipitation.

[0190] like Figure 3 As shown in a, compound 1 exhibits improved pharmacokinetic properties compared to compound 4.

[0191] like Figure 3 As shown in b, both Compound 1 and Compound 4 are converted to opicapone, wherein Compound 1 produces an opicapone pharmacokinetic profile similar to opicapone itself. Compared with opicapone from Compound 1 and opicapone, opicapone from Compound 4 exhibits inferior oral pharmacokinetic parameters.

[0192] Intravenous pharmacokinetics

[0193] The pharmacokinetic properties of Compound 1 and Compound 4 compared to micronized crystalline opicapone were evaluated by intravenous injection into 3 male Wistar rats (1 mg / kg; DMSO:20% HPBCD (1:9).

[0194] During the study, blood was collected from the jugular vein at different time points, centrifuged at 1500 x g for 15 min in a refrigerated centrifuge (4°C), and the obtained plasma was stored at -80°C until further analysis. The collected plasma samples were analyzed for compound 1, compound 4, and opicapone exposure. Bioanalysis involved the use of LC-MS / MS after plasma precipitation.

[0195] like Figure 4 As shown in a, compound 1 exhibits improved pharmacokinetic properties compared to compound 4.

[0196] like Figure 4 As shown in b, both Compound 1 and Compound 4 are converted to opicapone, where Compound 1 produces an opicapone pharmacokinetic profile similar to opicapone itself. Opicapone from Compound 4 exhibits inferior intravenous pharmacokinetic parameters compared to opicapone from Compound 1 and opicapone.

[0197] Subcutaneous pharmacokinetics

[0198] The pharmacokinetic properties of Compound 1 and Compound 4 were evaluated by subcutaneous injection into 4 male Wistar rats (3 mg / kg; DMSO:20% HPBCD (1:9)). The compounds showed a low level of irritation at the injection site.

[0199] During the study, blood was collected from the tail vein at different time points, centrifuged at 1500 x g for 15 min in a refrigerated centrifuge (4°C), and the obtained plasma was stored at -80°C until further analysis. The collected plasma samples were analyzed for compound 1, compound 4, and opicapone exposure. Bioanalysis involved the use of LC-MS / MS after plasma precipitation.

[0200] Table 2 shows the pharmacokinetic parameters of Compound 1 and Compound 4.

[0201] Table 2 - Pharmacokinetic parameters of Compound 1 and Compound 4 administered orally (po), intravenously (iv), and subcutaneously (sc)

[0202]

[0203] The pharmacokinetic parameters of opicapone converted from Compound 1 and Compound 4 are shown in Table 3 (together with the pharmacokinetic parameters of micronized crystalline opicapone).

[0204] Table 3 - Pharmacokinetic parameters of opicapone converted from the following compounds administered orally (po), intravenously (iv) and subcutaneously (sc)

[0205]

[0206]

[0207] like Figure 5 As shown in a, after oral administration, Compound 1 is converted to opicapone, resulting in a better pharmacokinetic profile of opicapone (AUC 最后 Surprisingly, unlike oral or intravenous administration, opicapone from Compound 1 exhibited an improved pharmacokinetic profile when administered subcutaneously (compared to orally administered opicapone).

[0208] like Figure 5 As shown in b, after oral administration, compound 4 is converted to opicapone, resulting in a more favorable opicapone pharmacokinetic profile (AUC 最后The pharmacokinetic profile of opicapone from compound 4 was significantly worse than that of opicapone from compound 1 when administered intravenously or orally, but it was similar to that of opicapone from compound 1 when administered subcutaneously. Such unusual pharmacodynamic behavior cannot be predicted by theory. In addition, compound 4 produced a higher C for opicapone than compound 1. 最大 , despite having a lower C 最大 .

[0209] Taken together, the data indicate that compound 1 is unexpectedly more stable than compound 4 when administered intravenously, indicating improved stability in the bloodstream. Likewise, the bioavailability of compound 1 is greater via the subcutaneous route, which is attributed to the Figure 5 Compared with compound 4 (■) in b, Figure 5 C of the prodrug of compound 1 (●) in a 最大 Therefore, it is particularly surprising that Figure 5 Compared with compound 1 (○) in a, Figure 5 Compound 4 (□) in b produced more opicapone. Compound 4 may have a different distribution pattern when administered subcutaneously and may find a stable reservoir in a specific tissue or blood binding site.

[0210] Subcutaneous Pharmacodynamics: COMT Inhibition

[0211] The pharmacodynamic properties of Compound 1 and Compound 4 were evaluated in comparison with orally administered micronized crystalline opicapone by subcutaneous injection into 4 male Wistar rats (3 mg / kg; DMSO:20% HPBCD (1:9)) followed by measurement of erythrocyte S-COMT activity over time.

[0212] During the study, blood was collected from the tail vein at different time points, centrifuged at 1500×g for 15 min in a refrigerated centrifuge (4° C.), and the obtained plasma and erythrocytes were stored at −80° C. until further analysis. The collected plasma samples were analyzed for Compound 1, Compound 4, and opicapone exposure as previously described.

[0213] Erythrocyte S-COMT activity is assessed by the ability of epinephrine methylation to metanephrine. By adding 4 volumes of ice-cold ultrapure water and homogenizing in a bead mill homogenizer using glass beads, aliquots of erythrocytes are subsequently dissolved by incubation on wet ice for 10 minutes. After centrifugation (20 000x g, 20 minutes, 4 ° C), the total protein of the supernatant containing S-COMT is quantitatively analyzed using Bradford assay. The supernatant is diluted with water to 4 mg total protein per ml. Then 100 μL of these diluted supernatants are pre-incubated for 20 min in 96-well plates with 80 μL phosphate buffer (10 mM, pH 7.8); Thereafter, in the presence of saturated concentrations of S-adenosyl-L-methionine (methyl donor) (500 μM), the reaction mixture is incubated with epinephrine (10 mM; 20 μL) for 10 min. The incubation medium also contains pargyline (100 μM), MgCl2 (100 μM) and EGTA (1 mM). Pre-incubation and incubation were performed at 37 ° C under dark conditions using continuous shaking and without oxygenation. At the end of the incubation period, the plate was transferred to ice and the reaction was stopped by adding 15 μL of glacial acetic acid. Each sample of 60 μL was then transferred to a new 96-well plate containing 400 μL of 0.1% formic acid, followed by centrifugation of the plate (2000 x g, 5 minutes, 4 ° C). The supernatant was used for quantitative metanephrine by LC-MS / MS.

[0214] like Figure 6 As shown in , the conversion of Compound 1 and Compound 4 to opicapone produced a rapid inhibition of COMT activity in erythrocytes, with a maximum effect 2 h after administration (96% and 94% inhibition for Compound 1 and Compound 4, respectively). COMT inhibition was maintained above 80% at least until 8 h after administration, much longer than that achieved with orally administered opicapone.

[0215] Subcutaneous pharmacodynamics: effects on L-DOPA

[0216] As proof of concept, the effect of compound 4 on L-DOPA metabolism was evaluated in 4 male Wistar rats. Animals were injected subcutaneously with a single formulation containing 12 mg / kg L-DOPA plus 3 mg / kg benserazide and with or without 3 mg / kg compound 4 in DMSO:PEG 400:30% SBEBCD (1:2:2). Plasma samples were collected as described above and analyzed for levels of L-DOPA and its metabolite 3-O-methyldopa (3-OMD).

[0217] like Figure 7 As shown in Figure 2, concomitant administration of compound 4 with L-DOPA / benserazide increased the circulating levels of L-DOPA (AUC 最后The level of its metabolite 3-OMD decreased accordingly.

[0218] Summarize

[0219] Subcutaneous administration was the route with the highest conversion of opicapone for both Compound 1 and Compound 4, with COMT inhibition above 80% at least until 8 hours after administration. Compound 4 showed increased L-DOPA levels and decreased 3-OMD levels when co-administered with L-DOPA / benserazide.

[0220] Other variations of the disclosed embodiments may be understood and effected by those skilled in the art in practicing the claimed invention, by studying the drawings, the disclosure, and the appended claims. In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein R is H or a C1-C6 alkyl group and n is 0 or 1.

2. The compound according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium salt, ammonium salt and potassium salt.

3. The compound according to claim 2, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium salt and ammonium salt.

4. The compound of claim 3, wherein the sodium salt is a disodium salt and wherein the ammonium salt is a triammonium salt.

5. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, the method comprising: (a) deprotecting a compound of formula (II) to provide a compound of formula (I): wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1; and (b) optionally converting the compound of formula (I) into a pharmaceutically acceptable salt thereof.

6. The method of claim 5, wherein the phosphate protecting groups R1 and R2 are each independently selected from the group consisting of C1-C6 alkyl and benzyl.

7. The method of claim 6, wherein the phosphate protecting groups R1 and R2 are both benzyl or both tert-butyl, or both ethyl.

8. The process of any one of claims 5 to 7, wherein step (a) is carried out by reacting the compound of formula (II) with trimethylsilyl halide in an aprotic solvent such as dichloromethane or acetonitrile, followed by aqueous work-up.

9. The method of claim 8, wherein the trimethylsilyl halide is trimethylsilyl bromide.

10. The method according to any one of claims 5 to 9, wherein the compound of formula (I) is converted into a pharmaceutically acceptable salt thereof.

11. The method of claim 10, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium salt, ammonium salt and potassium salt.

12. The method of claim 11, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium salts and ammonium salts.

13. The method of claim 12, wherein the sodium salt is a disodium salt and wherein the ammonium salt is a triammonium salt.

14. A method for preparing a compound of formula (II) as defined in claim 5, the method comprising: In the presence of a base and an aprotic solvent, a compound of formula (III): Reaction with a compound of formula (IV): wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1.

15. The method of claim 14, wherein the phosphate protecting groups R1 and R2 are each independently selected from the group consisting of C1-C6 alkyl and benzyl.

16. The method of claim 15, wherein the phosphate protecting groups R1 and R2 are both benzyl or both tert-butyl, or both ethyl.

17. The method of claim 14, wherein the base is triethylamine.

18. A compound of formula (II): wherein R1 and R2 are each independently a monovalent phosphate protecting group or together form a divalent phosphate protecting group; R is H or a C1-C6 alkyl group and n is 0 or 1.

19. The compound according to claim 18, wherein the phosphate protecting groups R1 and R2 are each independently selected from the group consisting of C1-C6 alkyl and benzyl.

20. The compound according to claim 19, wherein the phosphate protecting groups R1 and R2 are both benzyl or both tert-butyl, or both ethyl.

21. A pharmaceutical preparation, comprising: (i) a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof; and (ii) one or more pharmaceutically acceptable excipients.

22. A pharmaceutical preparation for intravenous administration to a human, the pharmaceutical preparation comprising: (i) a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable vehicle.

23. A pharmaceutical preparation for subcutaneous administration to a human, the pharmaceutical preparation comprising: (i) a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable vehicle.

24. A pharmaceutical formulation according to claim 21 or claim 22 or claim 23, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium salts, ammonium salts and potassium salts.

25. The pharmaceutical formulation according to claim 24, wherein the pharmaceutically acceptable salt thereof is selected from the group consisting of sodium salt and ammonium salt.

26. The pharmaceutical formulation of claim 25, wherein the sodium salt is a disodium salt and wherein the ammonium salt is a triammonium salt.

27. A pharmaceutical formulation according to any one of claims 22 to 26, wherein the pharmaceutically acceptable vehicle comprises water for injection.

28. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 or a pharmaceutical preparation according to any one of claims 21 to 27, for use in treating Parkinson's disease.

29. The compound or pharmaceutical formulation for use according to claim 28, wherein the compound or the pharmaceutical formulation is administered in combination with L-DOPA or phospho-L-DOPA.

30. The compound or pharmaceutical formulation for use according to claim 29, wherein the compound or the pharmaceutical formulation is administered in combination with an AADC inhibitor, preferably carbidopa, benserazide or foscarbidopa.

31. A compound or pharmaceutical formulation for use according to claim 28 or claim 29, wherein the compound or pharmaceutical formulation is administered in combination with L-DOPA and carbidopa or benserazide.

32. The compound or pharmaceutical formulation for use according to claim 28 or claim 29, wherein the compound or pharmaceutical formulation is administered in combination with fos-levodopa and fos-carbidopa.

33. A compound or pharmaceutical formulation for use according to any one of claims 28 to 32, wherein the compound or the pharmaceutical formulation is administered intravenously or subcutaneously, preferably subcutaneously.

34. A compound or pharmaceutical formulation for use according to any one of claims 28 to 32, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a daily dose equivalent to less than 25 mg per day of the compound of formula (III) as defined in claim 14.

35. A pharmaceutical formulation for use according to any one of claims 28 to 32, wherein the compound of formula (I) is administered in a daily dose equivalent to less than 50 mg per day of the compound of formula (III) as defined in claim 14.